Sustained MRD negativity & outcomes in myeloma, therapeutic targeting of VWF in TTP, and improving CAR T-cells in CLL with PI3 kinase inhibition

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Looking in the Mirror: The Moth Podcast 18 min · 25 Sep 2026 · The Moth

Trump hosts President Xi at state banquet 31 min · 25 Sep 2026 · Global News Podcast

TNA Reaction: Sawyer & Shaw Arrive 18 min · 25 Sep 2026 · Busted Open

NPR News: 09-25-2026 12AM EDT 5 min · 25 Sep 2026 · NPR News Now

12AM ET 09/25/2026 Newscast 3 min · 25 Sep 2026 · Fox News Hourly Update

The Lair of the White Worm 1h 0m · 25 Sep 2026 · How Did This Get Made?

Report any issue

Source

Recorded28 Jan 2022

Publisherfeeds.transistor.fm ↗

Handlerec:11742102

Show notes

On this week’s podcast, we’ll review a recent analysis of phase 3 daratumumab studies looking at the prognostic impact of sustained minimal residual disease, or MRD negativity in patients with multiple myeloma. Next, we’ll hear more about a novel thrombolytic agent targeting von Willebrand factor that may represent a promising approach for the treatment of thrombotic thrombocytopenic purpura. We’ll conclude with a study demonstrating that PI3 kinase inhibitor duvelisib can be used to enhance the in vivo efficacy of CAR T cells in CLL.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in